Beyond the Breathalyzer – Understanding the Drug Recognition Evaluation
A breathalyzer answers one question with precision: how much alcohol is in this person’s breath right now? It is a powerful tool — but only when alcohol is the substance in question. When a driver appears clearly impaired yet blows a 0.00, the breathalyzer offers nothing. Law enforcement is left with observable symptoms, no chemical confirmation, and a fundamental investigative problem: what is causing the impairment, and how do you document it in a way that holds up in court?
The Drug Recognition Evaluation — also called the Drug Recognition Expert program, or DRE — was developed precisely to address that problem. It is a structured, multi-step clinical assessment designed to identify drug-impaired drivers and classify the category of drug responsible. This article examines how the DRE program works, what science underpins it, and where its genuine limitations lie.
Origins of the DRE Program
The DRE protocol was developed in the early 1970s by officers of the Los Angeles Police Department, working alongside forensic scientists and physicians to create a systematic approach to drug impairment detection. After early field trials demonstrated promising results, the National Highway Traffic Safety Administration (NHTSA) and the International Association of Chiefs of Police (IACP) collaborated to standardize, validate, and expand the program nationally through the 1980s and 1990s. Today the DRE program operates in all 50 U.S. states, several Canadian provinces, and a growing number of countries worldwide.
Becoming a certified DRE is demanding. Candidates — who must already be experienced in standard SFST administration — complete over 72 hours of classroom instruction, pass multiple written examinations, conduct a minimum of 12 supervised drug influence evaluations across at least three of the seven drug categories, and achieve a 75% or higher toxicological confirmation rate on their certification evaluations. The program is administered jointly by NHTSA and the IACP, which also maintains the roster of certified DRE instructors and the standardized curriculum used nationally.
The Central Idea: Seven Drug Categories
The DRE system is built around a foundational insight: while hundreds of individual drugs exist, most substances that impair driving fall into one of seven pharmacological categories — and each category produces a recognizable, measurable pattern of physiological effects. A DRE officer is not trying to identify a specific molecule. They are trying to determine which category of drug is likely responsible for the observed impairment, then directing a toxicological sample to confirm that opinion.
| Drug Category | Common Examples | Key Observable Effects |
|---|---|---|
| CNS Depressants | Alcohol, benzodiazepines, barbiturates, sleep aids | Slowed reactions, droopy eyelids, slurred speech, reduced pulse and blood pressure, normal to constricted pupils |
| CNS Stimulants | Cocaine, methamphetamine, amphetamines, MDMA | Elevated pulse and blood pressure, raised body temperature, dilated pupils, increased muscle tone, agitation |
| Hallucinogens | LSD, psilocybin, mescaline, some MDMA | Dilated pupils, elevated pulse and blood pressure, disorganized thinking, sensory distortions |
| Dissociative Anesthetics | PCP, ketamine, dextromethorphan (DXM) | Markedly dilated pupils, elevated vital signs, rigid muscle tone, blank stare, disorientation, possible nystagmus in multiple planes |
| Narcotic Analgesics | Heroin, morphine, oxycodone, fentanyl | Constricted (pinpoint) pupils, drooping eyelids, slowed breathing, reduced pulse, track marks possible |
| Inhalants | Volatile solvents, aerosols, nitrous oxide | Disorientation, slurred speech, chemical odor, normal to dilated pupils, normal pulse |
| Cannabis | THC (smoked, vaped, edible), synthetic cannabinoids | Elevated pulse, slightly elevated blood pressure, reddened conjunctiva, rebound dilation, odor |
Because many people use more than one substance simultaneously — a combination known as polydrug use — the DRE protocol is designed to detect mixed presentations. A subject using both a stimulant and a depressant, for instance, may show conflicting indicators that a trained DRE officer is specifically prepared to recognize and interpret.
The 12-Step Protocol
The DRE evaluation follows a fixed 12-step sequence. The order matters — each step builds on the last, and deviation from the protocol can compromise the defensibility of the findings.
| Step | What Happens |
|---|---|
| 1. Breath alcohol test | Confirms or rules out alcohol as the sole or primary cause of impairment. A low or zero BAC in an obviously impaired subject is what typically triggers a DRE evaluation. |
| 2. Interview of arresting officer | The DRE gathers information about the subject’s driving behavior, appearance at the stop, and any statements made — establishing context before examining the subject. |
| 3. Preliminary examination | The DRE observes general appearance, speech, and behavior, and takes the first of three pulse readings. Conditions requiring medical attention are identified and addressed before the evaluation continues. |
| 4. Eye examinations | Three distinct eye tests are performed: Horizontal Gaze Nystagmus (HGN), Vertical Gaze Nystagmus (VGN), and Lack of Convergence. VGN and lack of convergence appear specifically with dissociative anesthetics and high-dose CNS depressants — distinguishing them from other categories. |
| 5. Divided attention tests | The Walk-and-Turn and One-Leg Stand from the standard SFST battery, plus the Romberg Balance test (estimating a 30-second interval with eyes closed) and the Finger-to-Nose test. |
| 6. Vital signs and second pulse | Blood pressure, body temperature, and pulse are measured and recorded. These readings are among the most diagnostically significant steps — stimulants reliably elevate all three, while depressants tend to lower them. |
| 7. Dark room examinations | Pupil size is measured in three lighting conditions — near-total darkness, indirect light, and direct light. Pupil response to light and resting pupil diameter vary systematically across drug categories and are recorded against standardized size charts. |
| 8. Muscle tone examination | The DRE assesses whether the subject’s muscle tone is normal, rigid (associated with stimulants and dissociatives), or flaccid (associated with depressants and narcotics). |
| 9. Injection site check and third pulse | The subject’s arms and other accessible areas are examined for injection marks. The third pulse reading is taken, providing a trend across the evaluation period. |
| 10. Subject’s statements | The DRE questions the subject about substance use, medications, medical conditions, and recent food or drink. Statements are documented but interpreted cautiously — self-report is useful context, not confirmation. |
| 11. Analysis and opinion | The DRE reviews all findings and forms a professional opinion: whether the subject is impaired, and if so, which drug category or categories are most likely responsible. |
| 12. Toxicological examination | A blood or urine sample is collected and submitted to a laboratory for chemical analysis. This is the essential confirmation step — the DRE’s opinion is an investigative conclusion, not a chemical identification. |
The Physiological Logic
What makes the DRE protocol more than a checklist is the internal logic connecting the steps. Each drug category produces a characteristic physiological signature — a predictable pattern across pupil size, vital signs, muscle tone, and eye behavior. The DRE is trained to recognize those patterns and to distinguish them from one another, including when they overlap in polydrug cases.
Pupil size is one of the most diagnostically useful indicators. The pupillometer — a standardized measurement tool — allows the DRE to record pupil diameter precisely rather than estimating it. Stimulants and hallucinogens typically produce dilation; narcotic analgesics produce marked constriction; cannabis produces a subtle rebound dilation; and dissociative anesthetics produce pronounced dilation combined with a characteristic blank, unfocused gaze. No single indicator is definitive — but the pattern across multiple steps builds toward a classification with genuine diagnostic power.
Validation Research and Accuracy
The DRE protocol has been subjected to a series of field validation studies, most significantly a large-scale national study conducted by Bierness and colleagues and published with NHTSA support. Across studies, DRE officers correctly identified drug category involvement — confirmed by subsequent toxicological testing — at rates generally ranging from 78% to 94%, depending on the study design, the drug categories examined, and whether polydrug cases were included.
Important caveats apply to those figures:
- Accuracy varies substantially by drug category — cannabis and stimulants tend to produce cleaner, more recognizable profiles; inhalants and polydrug combinations are considerably harder to classify correctly
- Most validation studies used experienced, well-trained DREs under relatively controlled conditions, which may overstate real-world performance
- Toxicological confirmation of drug presence is not the same as confirmation of impairment — a positive urine screen tells you a substance was used, not that it was causing impairment at the time of the evaluation
Criticism and Ongoing Debate
The DRE program has attracted sustained scientific and legal criticism since its inception, and the debate remains active. The core objections fall into three areas.
The training argument. DRE officers assess physiological indicators — blood pressure, pupil response, muscle tone — that fall within the traditional domain of medical professionals. Critics argue that a police officer, however well-trained, is not qualified to perform what is functionally a clinical examination and render a medical-style opinion about its cause. Proponents respond that DREs are not diagnosing medical conditions but identifying impairment patterns for investigative purposes — a meaningful but contested distinction.
The concentration problem. The DRE protocol identifies drug categories, not impairment levels. As with SFSTs, the presence of a drug — even at a concentration the DRE associates with impairment — does not establish that the subject was actually impaired to a specific degree at the time of driving. For most drugs, no equivalent of the 0.08% BAC standard exists. The gap between “drug detected” and “driver impaired” is wide, scientifically uncertain, and highly significant in legal proceedings.
The admissibility question. Courts across the United States have reached inconsistent conclusions about DRE evidence. Some jurisdictions admit DRE opinions freely; others apply rigorous gatekeeping standards and have excluded them; still others admit the behavioral observations while excluding the DRE’s categorical opinion about the drug involved. The scientific foundation of the program — sufficient for some courts, insufficient for others — continues to be litigated.
Conclusion
The Drug Recognition Evaluation represents a genuine and substantial advance over unstructured observation in the detection of drug-impaired driving. Its 12-step structure, grounded in measurable physiological indicators, gives officers a documented, systematic basis for forming and defending an opinion about drug impairment — something no tool previously provided at the roadside. But it is an investigative protocol, not a diagnostic instrument, and its conclusions are probabilistic rather than definitive. The toxicological confirmation step at the end of the process exists for exactly this reason: the DRE’s opinion points the investigation in a direction; the laboratory result determines whether that direction was correct. Understanding the difference between those two things — and what each one proves — is essential for anyone who encounters DRE evidence in a legal, clinical, or policy context.